AHA Guidelines Slide: DAPTStrategies in ACS

Dual Antiplatelet Therapy (DAPT) Strategies in Acute Coronary Syndrome

AHA/ACC Guideline-Based Approach for the First 12 Months

Acute coronary syndrome (ACS) includes ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. Platelet activation and thrombosis play a central role in these conditions.

Because of this, dual antiplatelet therapy (DAPT) — the combination of aspirin plus a P2Y12 inhibitor — is a cornerstone of treatment.

According to AHA/ACC guidelines, DAPT is recommended for 12 months in most patients with ACS, regardless of whether the patient is treated with medical therapy, PCI, or CABG, unless the risk of bleeding outweighs the ischemic benefit.

---

What is Dual Antiplatelet Therapy?

DAPT consists of:

1. Aspirin

2. A P2Y12 receptor inhibitor

The goal is to inhibit platelet aggregation through two different pathways, reducing the risk of:

Stent thrombosis

Recurrent myocardial infarction

Cardiovascular death

---

Recommended Antiplatelet Agents

Aspirin

Aspirin is the foundation of antiplatelet therapy.

Initial loading dose:

162–325 mg (chewed)

Maintenance dose:

75–100 mg daily indefinitely

Low-dose aspirin is preferred long term because it reduces bleeding risk without compromising efficacy.

---

P2Y12 Inhibitors

Three major agents are recommended.

Clopidogrel

Loading dose: 300–600 mg

Maintenance: 75 mg daily

Advantages:

Widely available

Lower bleeding risk

Limitations:

Variable response due to genetic polymorphisms.

---

Ticagrelor

Loading dose: 180 mg

Maintenance: 90 mg twice daily

Advantages:

More potent platelet inhibition

Superior to clopidogrel in ACS in several trials

Key consideration:

May cause dyspnea and bradyarrhythmias.

---

Prasugrel

Loading dose: 60 mg

Maintenance: 10 mg daily

Advantages:

Potent and consistent platelet inhibition

Contraindications:

History of stroke or TIA

Caution in patients ≥75 years or weight <60 kg.

---

Guideline-Preferred P2Y12 Inhibitor

According to AHA/ACC guidance:

Ticagrelor or prasugrel is preferred over clopidogrel in patients with ACS undergoing PCI, provided there are no contraindications.

Clopidogrel remains appropriate when:

Bleeding risk is high

Cost or availability limits use of newer agents

Patients require oral anticoagulation

---

DAPT Duration in ACS

Standard recommendation:

12 months of DAPT

This applies to:

STEMI

NSTEMI

Unstable angina

Regardless of treatment strategy:

PCI with stent

Medical therapy alone

CABG (after surgery when safe)

---

DAPT Strategy After PCI

After PCI for ACS:

Aspirin + P2Y12 inhibitor for 12 months

Key goals:

Prevent stent thrombosis

Reduce recurrent ischemic events

Drug-eluting stents require consistent antiplatelet therapy because early discontinuation significantly increases thrombotic risk.

---

Shortened DAPT in High Bleeding Risk

Some patients have significant bleeding risk:

Examples include:

Prior major bleeding

Elderly patients

Chronic kidney disease

Need for anticoagulation

In these patients:

Shorter DAPT (3–6 months) may be considered.

After stopping aspirin, P2Y12 inhibitor monotherapy may continue.

This strategy is increasingly supported by modern trials and guideline updates.

---

De-escalation Strategies

De-escalation refers to switching from a potent agent to a less potent one, usually:

Ticagrelor/Prasugrel → Clopidogrel

Reasons include:

Bleeding risk

Cost

Intolerance

This may be done:

Guided by platelet testing

Genotype-guided

Or clinically driven

---

DAPT in Patients Requiring Anticoagulation

Some ACS patients also require anticoagulation for conditions like:

Atrial fibrillation

Mechanical valves

Venous thromboembolism

Triple therapy (anticoagulant + aspirin + P2Y12 inhibitor) greatly increases bleeding risk.

Guideline approach:

Short duration triple therapy (≤1 week)

Followed by

Anticoagulant + clopidogrel

Aspirin is discontinued early to minimize bleeding.

---

Transition After 12 Months

After completing 12 months of DAPT, the next step depends on ischemic versus bleeding risk.

Options include:

Aspirin Alone

Most patients transition to aspirin monotherapy indefinitely.

Extended DAPT

Extended therapy may be considered in high ischemic risk patients such as:

Prior MI

Diabetes

Diffuse coronary disease

Multiple stents

However, bleeding risk must be carefully assessed.

---

Special Situations

CABG Patients

Patients undergoing CABG after ACS should resume P2Y12 inhibitor therapy post-surgery to complete 12 months of DAPT if bleeding risk allows.

---

Medically Managed ACS

Patients who do not undergo PCI should still receive:

Aspirin + P2Y12 inhibitor for 12 months

Ticagrelor is often preferred in this setting.

---

Practical Clinical Approach

A simplified decision framework:

Low bleeding risk

Aspirin + Ticagrelor/Prasugrel → 12 months

High bleeding risk

Short DAPT (3–6 months) → P2Y12 monotherapy

Need for anticoagulation

Short triple therapy → anticoagulant + clopidogrel

After 12 months

Aspirin alone or extended DAPT depending on ischemic risk.

---

Key Takeaways

Dual antiplatelet therapy is essential in ACS management.

Standard therapy is aspirin plus a P2Y12 inhibitor for 12 months.

Ticagrelor or prasugrel is preferred over clopidogrel when bleeding risk allows.

Shorter DAPT may be used in high bleeding risk patients.

Triple therapy should be minimized in patients requiring anticoagulation.

After one year, therapy should be individualized based on ischemic vs bleeding risk.

---

Guideline-directed DAPT strategies have significantly improved outcomes in ACS by reducing recurrent myocardial infarction, stent thrombosis, and cardiovascular death, while modern approaches increasingly focus on balancing ischemic protection with bleeding safety.